CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 10-Q | 2026-05-15 | English | |
| FORM 8-K | 2026-05-14 | English | |
| 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | |
| 424B4 | 2026-05-13 | English | |
| Regulatory Filings 2026 | 2026-05-12 | English | |
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46362719 | FORM 10-Q | 2026-05-15 | English | ||
| 46274090 | FORM 8-K | 2026-05-14 | English | ||
| 45766521 | 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | ||
| 46081758 | 424B4 | 2026-05-13 | English | ||
| 46081745 | Regulatory Filings 2026 | 2026-05-12 | English | ||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 46081761 | DEL AM | 2026-04-24 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
2 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
SensoDetect AB
Develops AI decision-support solutions for mental illness d…
|
SDET | SE | Professional, scientific and te… |
|
Sensorion
Clinical-stage biotech developing novel therapies for inner…
|
ALSEN | FR | Professional, scientific and te… |
|
Senti Biosciences, Inc.
Clinical-stage biotech developing cell and gene therapies u…
|
SNTI | US | Professional, scientific and te… |
|
SeouLinBioscienceCO.,LTD.
A solutions provider for life sciences, supplying research …
|
038070 | KR | Professional, scientific and te… |
|
Septerna, Inc.
Clinical-stage biotech developing oral small molecule medic…
|
SEPN | US | Professional, scientific and te… |
|
Sernova Biotherapeutics Inc.
Developing regenerative medicine using the Cell Pouch platf…
|
SVA | CA | Professional, scientific and te… |
|
SHANGHAI INNOSTAR BIO-TECH CO., LTD.
CRO specializing in GLP-compliant preclinical drug safety a…
|
688710 | CN | Professional, scientific and te… |
|
Shanghai Medicilon Inc.
Integrated drug discovery and preclinical services for glob…
|
688202 | CN | Professional, scientific and te… |
|
SHANGHAI MODEL ORGANISMS CENTER, INC.
Develops genetically engineered animal models and provides …
|
688265 | CN | Professional, scientific and te… |
|
SHANGHAI OPM BIOSCIENCES CO., LTD.
Provides cell culture media and CDMO services for biopharma…
|
688293 | CN | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.